Inhaler treatment for lung cancer

	Tweet

Lung cancer patients could receive safer and more efficient treatment through a system being developed by researchers at the University of Strathclyde in Glasgow.

The scientists have devised a method for giving drugs by inhalation to patients through a nebuliser, rather than the current approach of intravenous delivery.

The system could administer the treatment far more quickly than existing methods and without the harmful side effects associated with current systems, which can cause kidney damage.

It could also enable health authorities to deliver the drugs in smaller doses without diminution of benefit to patients.

Lung cancer and mesothelioma caused 4,147 deaths in Scotland in 2009, and deaths of women from the disease increased by 12% in the preceding decade, despite a corresponding fall of 20% among men.

Dr Chris Carter, a Senior Lecturer the Strathclyde Institute of Pharmacy and Biomedical Sciences, led the research, partnered by Professor Alex Mullen and Dr Valerie Ferro. She said: “Increasing awareness of cancer risks and improvements in treatment do not alter the fact that it remains one of Scotland’s biggest killers and lung cancer is its most common form. This means that new, improved treatments are still essential.

“By delivering cisplatin, one of the most widely used drugs for lung cancer, in a vaporised form, we would be able to get it to the cancerous cells and avoid the damage to healthy cells which can be hugely debilitating to patients. It would make the treatment far less onerous for them and we hope it would help them to live longer.”

The research is an example of the pioneering work of the Strathclyde Institute of Pharmacy and Biomedical Sciences in developing new medicines for illnesses and conditions including infectious diseases, cancer, heart disease, and schizophrenia. An £8 million fundraising campaign is underway for the Institute’s new £36 million building, to expand and enhance its innovative research and education in medicine discovery, development and use.

The research received funding from Scottish Enterprise’s Proof of Concept Programme, which supports the pre-commercialisation of leading-edge technologies emerging from Scotland’s universities, research institutes and NHS Boards. It helps researchers to export their ideas and inventions from the lab to the global marketplace and create new sustainable technology businesses in Scotland or license the technology to Scottish companies.

###

The programme is developed and operated by Scottish Enterprise in partnership with key stakeholders including: Scottish Government, Universities Scotland and the Scottish Funding Council. It is partly funded by the European Union.

###

Corporate Comms
corporatecomms@strath.ac.uk
44-141-548-2370
University of Strathclyde

RELATED STORIES:
Blood test may find early lung cancer: study   TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer   Lung Cancer Screening Wins More Support   Blacks more likely to die of curable lung cancer than whites   Cancer risks of eating red and processed meat   Vitamins don’t reduce risk of lung cancer   Marijuana tied to precancerous lung changes   Burning incense increases risk of respiratory tract cancers   Pistachios May Reduce Lung Cancer Risk   Guide on Lung Cancer in “Never-smokers”: a Different Disease and Different Treatments   Promising Strategy for Treatment of Lung Cancer   Video-assisted thoracic surgery valuable tool in lung cancer screening   Elderly Dutch lung patients’ survival improved by new treatment options between 2003-2009   Secondhand smoke exposure in childhood increases lung cancer risk later in life   Lung cancer pill on NHS in 2007   Missing protein may hold lung cancer key   Heavy marijuana use not linked to lung cancer   Genetic Region Linked to a Five Times Higher Lung Cancer Risk   Gene fusion in lung cancer afflicting never-smokers may be target for therapy   New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer   New study casts doubt on lung cancer treatment   Dietary boron reduces lung cancer risk in women

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]